This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (11)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Oncology  • Alert me on articles by topic

Where to GO From Here?

Paul Graham Fisher, MD; Patricia A. Buffler, PhD

JAMA. 2005;293:615-617.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Brain tumor is one of the diagnoses most feared by patients, physicians, and even oncologists. Their fear is justified. More than half of the 18 400 primary malignant brain tumors diagnosed each year in the United States are malignant gliomas¹ that not only confer high risk for death and severe disability, but also steal what is held so highly as the essence of human life: the mind and spirit. In this issue of JAMA, Chang et al² use data from the Glioma Outcomes (GO) Project to provide a "report card" on the patterns of care in patients with newly diagnosed malignant gliomas; unfortunately, the grades are sobering. Consequently, this is an appropriate time to reflect on the past and current status of glioma treatment and suggest where to go from here.

Seventy-seven years ago, also in JAMA, Dandy³ described the hemispherectomy, . . . [Full Text of this Article]

Author Affiliations: Departments of Neurology, Pediatrics, Neurosurgery, and Human Biology, The Beirne Family Director of Neuro-Oncology at Packard Hospital, Stanford University, Stanford, Calif (Dr Fisher); Department of Epidemiology, Kenneth and Marjorie Kaiser Endowed Chair in Cancer Epidemiology, School of Public Health, University of California, Berkeley (Dr Buffler).

RELATED ARTICLE

Patterns of Care for Adults With Newly Diagnosed Malignant Glioma
Susan M. Chang, Ian F. Parney, Wei Huang, Frederick A. Anderson, Jr, Anthony L. Asher, Mark Bernstein, Kevin O. Lillehei, Henry Brem, Mitchel S. Berger, Edward R. Laws, and for the Glioma Outcomes Project Investigators
JAMA. 2005;293(5):557-564.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Akt-Dependent Proapoptotic Effects of Dietary Restriction on Late-Stage Management of a Phosphatase and Tensin Homologue/Tuberous Sclerosis Complex 2-Deficient Mouse Astrocytoma
Marsh et al.
Clin. Cancer Res. 2008;14:7751-7762.
ABSTRACT | FULL TEXT  

Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience
Attenello et al.
Ann. Surg. Oncol. 2008;15:2887-2893.
ABSTRACT | FULL TEXT  

Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV{Delta}M51) on Multifocal and Invasive Gliomas.
Lun et al.
JNCI J Natl Cancer Inst 2006;98:1546-1557.
ABSTRACT | FULL TEXT  

Re-evaluation of the cost effectiveness of temozolomide for malignant gliomas in British Columbia
Mabasa and Taylor
J Oncol Pharm Pract 2006;12:105-111.
ABSTRACT  

Advances Toward an Understanding of Brainstem Gliomas
Donaldson et al.
JCO 2006;24:1266-1272.
ABSTRACT | FULL TEXT  

Targeted Therapy With Antineoplastons A10 and AS2-1 of High-Grade, Recurrent, and Progressive Brainstem Glioma.
Burzynski et al.
Integr Cancer Ther 2006;5:40-47.
ABSTRACT  

Patterns of Care for Adults With Malignant Glioma
Shannon et al.
JAMA 2005;293:2469-2470.
FULL TEXT  

Patterns of Care for Patients with Malignant Glioma
JWatch Neurology 2005;2005:4-4.
FULL TEXT